| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep ...
The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatme...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 pri...
Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(...
This meeting aims to discuss the company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breas...
Raymond James analyst Rahul Sarugaser initiates coverage on Oncolytics Biotech (NASDAQ:ONCY) with a Outperform rating and an...
